Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)

Market Cap	8.06B +66.2%
Revenue (ttm)	277.12M +37.5%
Net Income	-419.34M
EPS	-0.75
Shares Out	562.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,485,245
Average Volume	22,114,448
Open	14.22
Previous Close	14.32
Day's Range	13.94 - 14.39
52-Week Range	6.80 - 18.11
Beta	0.47
RSI	53.81
Earnings Date	Apr 18, 2026

About Jiangsu Yahong Meditech

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis and surgery indication; APL-1202, an oral reversible MetAP2 inhibitor for untreated intermediate-risk NMIBC and neoadjuvant therapy before muscle-invas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 399
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688176

Financial Performance

In 2025, Jiangsu Yahong Meditech's revenue was 277.12 million, an increase of 37.49% compared to the previous year's 201.56 million. Losses were -419.34 million, 9.19% more than in 2024.